AB-PA01 is a 4-phage investigational therapeutic being developed for treatment of P. aeruginosa infections, including MDR strains. In preclinical studies, AB-PA01 demonstrated broad activity against 70-80% of global P. aeruginosa clinical isolates and against biofilms. The phages can survive nebulization, potentially allowing for an inhaled formulation for lung infections, including those in patients with cystic fibrosis. Additional target indications include complicated UTI caused by MDR organisms, complicated intra-abdominal infections, MDR lung infections, bacteremia, otitis and others.